Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban in Recent Acute Coronary Syndrome (Phase 3, Event-Driven)
2008-002708-25Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS) comparing Rivaroxaban + standard care with Placebo + standard care (2 arms). Primary endpoint: Composite of cardiovascular death, myocardial infarction, or stroke. Started Oct 2008; status: completed.
02
Drugs
rivaroxaban
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2008-002708-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002708-25.